Monte Rosa Therapeutics Inc. Common Stock (GLUE)

About GLUE

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and sy…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

173

Website

www.monterosatx.com/

Fundamentals

1-day range

$13.37$14.3

Market cap

$1.30B

P/E (trailing)

—

P/E (forward)

-7.13

EPS (trailing)

$-1.74

Dividend yield

—

Beta

1.31

Avg. volume

1.44M

Forecasts

6 analyst ratings

Monte Rosa Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• GLUE

  Monte Rosa Therapeutics Inc. Common Stock

  $13.37

  ▼ 6.63%
  Market cap $1.30BP/E —
  $4.6$25.77
• INBX

  Inhibrx Biosciences Inc. Common Stock

  $123.93

  ▼ 0.00%
  Market cap $1.21BP/E —
  $26.19$155.29
• IMTX

  Immatics N.V. Ordinary Shares

  $9.45

  ▲ 0.91%
  Market cap $1.21BP/E —
  $5.05$12.41
• VOR

  Vor Biopharma Inc. Common Stock

  $22.66

  ▼ 3.70%
  Market cap $1.16BP/E —
  $6.5$49.95
• MGTX

  MeiraGTx Holdings plc Ordinary Shares

  $13.8

  ▼ 2.40%
  Market cap $1.10BP/E 15.54
  $6.62$15.35
• RXRX

  Recursion Pharmaceuticals Inc. Class A Common Stock

  $3.33

  ▼ 3.20%
  Market cap $1.69BP/E —
  $2.77$7.18
• SANA

  Sana Biotechnology Inc. Common Stock

  $3.93

  ▼ 3.91%
  Market cap $884.97MP/E —
  $2.61$6.55

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Guggenheim Reiterates Buy on Monte Rosa Therapeutics, Maintains $28 Price Target
  benzinga · 8/25/2026
• Guggenheim Reiterates Buy on Monte Rosa Therapeutics, Maintains $28 Price Target
  Benzinga · 8/25/2026
• Monte Rosa Therapeutics Says First Patient Dosed In Modefire-1, Phase 2 Study Evaluating MRT-2359 In Combination With Apalutamide In Patients With mCRPC With AR Mutations
  Benzinga · 8/24/2026
• JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $27
  Benzinga · 8/7/2026
• Guggenheim Maintains Buy on Monte Rosa Therapeutics, Lowers Price Target to $28
  Benzinga · 8/7/2026
• Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $27
  Benzinga · 8/7/2026
• Monte Rosa Therapeutics (NASDAQ:GLUE) Beats Q2 Revenue Estimates but Posts Wider Loss
  ChartMill · 8/6/2026
• Monte Rosa Therapeutics Q2 EPS $(0.43) Misses $(0.38) Estimate, Sales $8.968M Beat $5.524M Estimate
  Benzinga · 8/6/2026
• Wedbush Maintains Outperform on Monte Rosa Therapeutics, Lowers Price Target to $27
  Benzinga · 8/3/2026

• Markus Warmuth · July 16, 2026 · Sale

  9.5K @ $23.18
• Jennifer Champoux · July 15, 2026 · Option Exercise

  4.4K @ $3.98
• Jennifer Champoux · July 15, 2026 · Sale

  4.4K @ $23.38
• Sharon Townson · July 6, 2026 · Option Exercise

  6.0K @ $6.14
• Sharon Townson · July 6, 2026 · Sale

  400 @ $24.13
• Sharon Townson · July 6, 2026 · Sale

  5.6K @ $23.25
• Ali Behbahani · July 1, 2026 · J

  15.0K
• Ali Behbahani · July 1, 2026 · J

  1.00M
• Filip Janku · June 30, 2026 · Option Exercise

  5.4K @ $13.41
• Filip Janku · June 30, 2026 · Sale

  5.4K @ $24.5
• Filip Janku · June 24, 2026 · Option Exercise

  30.0K @ $7.56
• Filip Janku · June 24, 2026 · Sale

  30.0K @ $21.42
• Filip Janku · June 23, 2026 · Option Exercise

  6.0K @ $7.56
• Filip Janku · June 23, 2026 · Sale

  11.8K @ $20.22
• Sharon Townson · June 23, 2026 · Option Exercise

  3.0K @ $6.14

Institutional Ownership

March 31, 2026

Total shares held

86.17M

Total value held

$1.30B

Institutional holders

184